Clinical trial · Interventional
MSCs for the Treatment of Burn Wounds
Allogenic Mesenchymal Stromal Cells for the Treatment of Burn Wounds.
NCT06103409CI-TRIAL-00070796unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this study is to evaluate the capacity of allogenic mesenchymal stromal cells form bone marrow (BM-MSC) or adipose tissue(Ad-MSC) to induce wound healing in patients with burn wounds.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Burn Wound | — | UNRESOLVED | — |
| Second- or Third-degree Burn | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Implantation of allogeneic MSCs on burn wounds | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Allogenic MSCs
- description
- All Patients will receive conservative treatment before transplantation of allogenic MSCs embedded in autologous platelet rich plasma clot.
- interventionNames
- Biological: Implantation of allogeneic MSCs on burn wounds
Primary outcomes (2)
- measure
- Re-epithelialization areas
- timeFrame
- Up to 6 month
- description
- Re-epithelialization will be determined by clinical evaluations and recorded by digital color photographs
- measure
- Complete burn wound healing
- timeFrame
- Up to 12 month
- description
- Time (days) to complete re-epithelialization of burned skin. It will be based on clinical evaluations and digital color photographs
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 2 Weeks
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Age between 2 weeks and 85 years old * Patient with second- or third-degree burn (AB/B or B). * Thermal burns * Electrical burns * Chemical burns * Informed consent of the patient or caretaker Exclusion Criteria: * First degree burn (A or AB) * Evidence of active infection at the wound site * Chronic malnutrition * Systemic inflammatory response syndrome (SIRS) or sepsis * Moderate or severe respiratory tract or lungs burn injuries * Autoimmune disease (e.g. multiple sclerosis, lupus erythematosus) * Severe pulmonary disease, hematologic disease, malignancy, or hypo-immunity. * Diabetes * Pregnancy
References
Publications (4)
- BACKGROUNDWittig O, Diaz-Solano D, Chacin T, Rodriguez Y, Ramos G, Acurero G, Leal F, Cardier JE. Healing of deep dermal burns by allogeneic mesenchymal stromal cell transplantation. Int J Dermatol. 2020 Aug;59(8):941-950. doi: 10.1111/ijd.14949. Epub 2020 Jun 5. PMID 32501530
- BACKGROUNDPereira B, Duque K, Ramos-Gonzalez G, Diaz-Solano D, Wittig O, Zamora M, Gledhill T, Cardier JE. Wound healing by transplantation of mesenchymal stromal cells loaded on polyethylene terephthalate scaffold: Implications for skin injury treatment. Injury. 2023 Apr;54(4):1071-1081. doi: 10.1016/j.injury.2023.02.024. Epub 2023 Feb 13. PMID 36801131
- BACKGROUNDRamos-Gonzalez G, Salazar L, Wittig O, Diaz-Solano D, Cardier JE. The effects of mesenchymal stromal cells and platelet-rich plasma treatments on cutaneous wound healing. Arch Dermatol Res. 2023 May;315(4):815-823. doi: 10.1007/s00403-022-02451-y. Epub 2022 Nov 3. PMID 36326886
- BACKGROUNDRamos-Gonzalez G, Wittig O, Diaz-Solano D, Salazar L, Ayala-Grosso C, Cardier JE. Evaluation of epithelial progenitor cells and growth factors in a preclinical model of wound healing induced by mesenchymal stromal cells. Biosci Rep. 2020 Jul 31;40(7):BSR20200461. doi: 10.1042/BSR20200461. PMID 32667622